Literature DB >> 28514610

Osimertinib in EGFR T790M-Positive Lung Cancer.

Tony S Mok1, Yi-Long Wu2, Vassiliki A Papadimitrakopoulou3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28514610     DOI： 10.1056/NEJMc1703339

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy.

Authors:  Emil Lou
Journal:  Ann Transl Med       Date:  2018-05

2.  Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.

Authors:  Tejas Patil; Rao Mushtaq; Sydney Marsh; Christine Azelby; Miheer Pujara; Kurtis D Davies; Dara L Aisner; William T Purcell; Erin L Schenk; Jose M Pacheco; Paul A Bunn; D Ross Camidge; Robert C Doebele
Journal:  Clin Lung Cancer       Date:  2019-11-21       Impact factor: 4.785

3.  A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).

Authors:  Kazuhiro Asami; Masahiko Ando; Takashi Nishimura; Takashi Yokoi; Atsuhisa Tamura; Koichi Minato; Masahide Mori; Fumitaka Ogushi; Akiyoshi Yamamoto; Hiroshige Yoshioka; Masaaki Kawahara; Shinji Atagi
Journal:  Thorac Cancer       Date:  2022-05-13       Impact factor: 3.223

Review 4.  Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.

Authors:  Zhengyang Hu; Ming Li; Zhencong Chen; Cheng Zhan; Zongwu Lin; Qun Wang
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.

Authors:  Feliciano Barrón; Andrés F Cardona; Luis Corrales; Laura-Alejandra Ramirez-Tirado; Enrique Caballe-Perez; Gisela Sanchez; Diana Flores-Estrada; Zyanya Lucia Zatarain-Barrón; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

6.  Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer.

Authors:  Habeeb Majeed; Eitan Amir
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 7.  Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.

Authors:  Robert Campbell; Geoffrey Chong; Eliza A Hawkes
Journal:  J Clin Med       Date:  2018-03-21       Impact factor: 4.241

8.  A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer.

Authors:  Wei You; Mei Liu; Ji-Dong Miao; Yu-Qian Liao; Yi-Bing Song; Dian-Kun Cai; Yang Gao; Hao Peng
Journal:  J Cancer       Date:  2018-03-10       Impact factor: 4.207

Review 9.  Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.

Authors:  Andreas Tiefenbacher; Robert Pirker
Journal:  Memo       Date:  2018-05-18

10.  Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer.

Authors:  Tejas Patil; Jose M Pacheco; Anastasios Dimou; William T Purcell; Candice Rossi; Paul A Bunn; Robert C Doebele; D Ross Camidge; Lisa Ferrigno
Journal:  Front Oncol       Date:  2020-04-15       Impact factor: 5.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.